Clinical Lymphoma, Myeloma and Leukemia

Published by: Elsevier Inc.  

People

  1. Derkach
    Derkach
  2. Hultcrantz
    Hultcrantz
  3. Hassoun
    Hassoun
  4. Korde
    Korde
  5. Lesokhin
    Lesokhin
  6. Mailankody
    Mailankody
  7. Shah
    Shah
  8. Tan
    Tan
  9. Giralt
    Giralt
  10. Maclachlan
    Maclachlan

Groups

  1. Biostatistics Service (16)
  2. Center for Hematologic Malignancies (16)
  3. Department of Medicine (16)
  4. Epidemiology and Biostatistics (16)
  5. Hematologic Malignancies, Division of (16)
  6. Population Sciences Research Program (16)
  7. GME, Medicine (14)
  8. Graduate Medical Education (14)
  9. Myeloma (14)
  10. Sloan Kettering Institute Postdocs (14)
Search Within
  1. "Andriy Derkach"
Formats
  1. Meeting Abstract (16)
Groups
  1. Biostatistics Service (16)
  2. Center for Hematologic Malignancies (16)
  3. Department of Medicine (16)
  4. Epidemiology and Biostatistics (16)
  5. Hematologic Malignancies, Division of (16)
  6. Population Sciences Research Program (16)

More Groups

People
  1. Andriy Derkach (16)
  2. Malin Hultcrantz (14)
  3. Alexander Lesokhin (13)
  4. Carlyn Rose Tan (13)
  5. Hani Hassoun (13)
  6. Neha Korde (13)

More People

Years
  1. 2023 (8)
  2. 2022 (6)
  3. 2021 (2)
Publishers
  1. Elsevier Inc. (16)

Results (16)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A whole foods plant-based weight loss intervention improves metabolic and immune biomarkers in MGUS/SMM patients as well as progression trajectory in a subset: The NUTRIVENTION trial
    Meeting Abstract

    Shah, U.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Hosszu, K.; Pollak, M.; Mailankody, S.; Korde, N.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Mailankody, S.; Lahoud, O.; Landau, H.; Chung, D.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Individualized risk in newly diagnosed multiple myeloma
    Meeting Abstract

    Maura, F.; Rajanna, A.; Ziccheddu, B.; Derkach, A.; Poos, A.; Maclachlan, K.; Boyle, E.; Hultcrantz, M.; Silva, A.; Jackson, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C. R.; Maclachlan, K.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Patel, D.; Shekarkhand, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evolving M-spike and risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Nemirovsky, D.; Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evaluating dynamic changes in the serum free light chain ratio and its effect on risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Comprehensive genomic characterization of response and resistance to daratumumab based quadruplet induction in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K.; Tan, C. R.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; McPherson, A.; Diamond, B.; Blaney, P.; Ziccheddu, B.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • SVR (spleen volume reduction) predicts OS (overall survival) in MF (myelofibrosis) patients on PAC (pacritinib) but not BAT (best available therapy): PERSIST-2 landmark OS analysis
    Meeting Abstract

    Ajufo, H.; Bewersdorf, J. P.; Harrison, C.; Palandri, F.; Mascarenhas, J.; Palmer, J.; Gerds, A.; Kiladjian, J. J.; Buckley, S.; Derkach, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Outcomes based on sequential use of venetoclax based therapy and targeted therapy in acute myeloid leukemia (AML)
    Meeting Abstract

    Stahl, M.; Shallis, R. M.; Derkach, A.; Goldberg, A. D.; Stein, A.; Stein, E. M.; Marcucci, G.; Zeidan, A. M.; Shimony, S.; DeAngelo, D. J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • A pilot plant based dietary intervention in MGUS and SMM is feasible and associated with reduction in insulin and leptin levels
    Meeting Abstract

    Shah, U.; Castro, F.; Anuraj, A.; Blaslov, J.; Adintori, P.; Derkach, A.; Pollak, M.; Maclachlan, K.; Mailankody, S.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save

    • Clinical Lymphoma, Myeloma and Leukemia – authorized name for:

    Name ISSN / ISBN Publisher
    Clinical Lymphoma Myeloma & Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma Myeloma & Leukemia 2152-2650 Cancer Media Group
    Clinical Lymphoma Myeloma & Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma Myeloma & Leukemia 2152-2650 Cig Media Group, Lp
    Clinical Lymphoma, Myeloma & Leukemia 21522669 Unknown
    Clinical Lymphoma, Myeloma & Leukemia 2152-2650 Unknown
    Clinical Lymphoma, Myeloma & Leukemia 1368-8375 Unknown
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522669 Unknown
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 Unknown
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 152-2650 2021
    Clinical Lymphoma, Myeloma and Leukemia 21522650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 Elsevier Ltd
    Clinical Lymphoma, Myeloma and Leukemia 21522650 2022
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 2023
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522669 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 The Author(s)
    Clinical Lymphoma, Myeloma and Leukemia 21522650 The Authors
    Clinical Lymphoma, Myeloma and Leukemia 21522650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 2021
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.